Tien Liang BioTech Co., Ltd. (TPEX:4127)
Taiwan · Delayed Price · Currency is TWD 45.60
-1.90 (-4.00%)
Sep 30, 2026, 1:30 PM CST
Tien Liang BioTech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,174 | 1,419 | 1,899 | 664 | 707 | 677 | |
Market Cap Growth | 36.89% | -25.30% | 186.21% | -6.15% | 4.39% | 32.14% |
Enterprise Value | 2,574 | 1,850 | 1,835 | 619 | 721 | 727 |
Last Close Price | 47.50 | 31.00 | 41.50 | 14.30 | 15.23 | 14.59 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 31.46 | - | 162.37 | 37.42 | 11.89 | 14.53 |
Forward PE | - | 10.79 | 10.79 | 10.79 | 10.79 | 10.79 |
PS Ratio | 3.34 | 2.77 | 4.93 | 1.44 | 1.34 | 1.19 |
PB Ratio | 4.19 | 2.99 | 3.97 | 1.35 | 1.49 | 1.64 |
P/TBV Ratio | 4.19 | 3.00 | 3.98 | 1.35 | 1.49 | 1.64 |
P/FCF Ratio | 89.52 | - | 42.57 | 10.25 | 33.88 | 15.18 |
P/OCF Ratio | 46.14 | 73.76 | 39.03 | 9.52 | 32.31 | 14.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.96 | 3.62 | 4.76 | 1.35 | 1.37 | 1.27 |
EV/EBITDA Ratio | 155.50 | - | 198.41 | 21.48 | 10.56 | 13.43 |
EV/EBIT Ratio | - | - | 3094.22 | 32.79 | 12.37 | 16.93 |
EV/FCF Ratio | 106.03 | - | 41.13 | 9.57 | 34.56 | 16.30 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.15 | 1.26 | 0.70 | 0.14 | 0.21 | 0.32 |
Debt / EBITDA Ratio | 36.12 | - | 34.42 | 2.42 | 1.47 | 2.42 |
Debt / FCF Ratio | 24.63 | - | 7.52 | 1.10 | 4.86 | 2.97 |
Net Debt / Equity Ratio | 0.77 | 0.94 | 0.43 | -0.14 | -0.01 | 0.03 |
Net Debt / EBITDA Ratio | 24.21 | -67.78 | 22.14 | -2.48 | -0.09 | 0.26 |
Net Debt / FCF Ratio | 16.51 | -112.46 | 4.59 | -1.10 | -0.31 | 0.32 |
Asset Turnover | 0.57 | 0.49 | 0.50 | 0.69 | 0.79 | 0.89 |
Inventory Turnover | 4.53 | 3.57 | 2.31 | 2.04 | 2.46 | 4.11 |
Quick Ratio | 0.35 | 0.28 | 0.42 | 1.50 | 1.11 | 0.97 |
Current Ratio | 0.45 | 0.40 | 0.61 | 2.13 | 1.76 | 1.32 |
Return on Equity (ROE) | 14.25% | -2.15% | 2.41% | 3.66% | 13.38% | 11.93% |
Return on Assets (ROA) | 0.31% | -0.97% | 0.05% | 1.77% | 5.47% | 4.19% |
Return on Invested Capital (ROIC) | 0.61% | -2.02% | 0.10% | 4.08% | 13.00% | 9.61% |
Return on Capital Employed (ROCE) | 1.10% | -3.40% | 0.10% | 3.70% | 11.90% | 10.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.18% | -0.72% | 0.62% | 2.67% | 8.41% | 6.88% |
FCF Yield | 1.12% | -0.28% | 2.35% | 9.75% | 2.95% | 6.59% |
Dividend Yield | - | - | - | 3.50% | - | - |
Payout Ratio | - | - | 195.62% | - | - | - |
Buyback Yield / Dilution | - | 0.01% | 0.04% | -0.01% | -0.05% | - |
Total Shareholder Return | - | 0.01% | 0.04% | 3.49% | -0.05% | - |